Managing Hypertension Using Combination Therapy



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2008 May 1;77(9):1279-1286.

  Patient information: See related handout on hypertension, written by the author of this article.

Combination therapy of hypertension with separate agents or a fixed-dose combination pill offers the potential to lower blood pressure more quickly, obtain target blood pressure, and decrease adverse effects. Antihypertensive agents from different classes may offset adverse reactions from each other, such as a diuretic decreasing edema occurring secondary to treatment with a calcium channel blocker. Most patients with hypertension require more than a single antihypertensive agent, particularly if they have comorbid conditions. Although the Joint National Committee guidelines recommend diuretic therapy as the initial pharmacologic agent for most patients with hypertension, the presence of “compelling indications” may prompt treatment with antihypertensive agents that demonstrate a particular benefit in primary or secondary prevention. Specific recommendations include treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, beta blockers, or aldosterone antagonists for hypertensive patients with heart failure. For hypertensive patients with diabetes, recommended treatment includes diuretics, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and/or calcium channel blockers. Recommended treatment for hypertensive patients with increased risk of coronary disease includes a diuretic, beta blockers, angiotensin-converting enzyme inhibitors, and/or calcium channel blocker. The Joint National Committee guidelines recommend beta blockers, angiotensin-converting enzyme inhibitors, and aldosterone antagonists for hypertensive patients who are postmyocardial infarction; angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertensive patients with chronic kidney disease; and diuretic and angiotensin-converting enzyme inhibitors for recurrent stroke prevention in patients with hypertension.

Combination therapy is treatment with two or more agents administered separately or in a fixed-dose combination pill and is required by most patients with hypertension to reach target blood pressure.1,2 In many cases, combination therapy improves rates of blood pressure control and requires less time to achieve target blood pressure1,3,4 with equivalent5 or better tolerability6 than higher-dose monotherapy. Additional benefits may include cost savings and better compliance.4,68

Potential disadvantages include increased cost for some combinations, increased risk of adverse events and drug-drug interactions, and patients' perception that taking more medications is equated with being sicker (this may be partially addressed by the use of a fixed-dose combination pill).9

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Combination therapy may be considered as the initial therapy to treat blood pressure that is more than 20/10 mm Hg over goal.

B

1, 3, 4

Combination therapy may be equally or better tolerated than higher doses of an individual component of the combination therapy.

B

4, 7, 12

The recommended initial treatment for hypertensive patients with heart failure or previous myocardial infarction includes a beta blocker and an ACE inhibitor.

A

1, 31, 32

For patients in whom an ACE inhibitor is recommended, an angiotensin receptor blocker may be substituted if the ACE inhibitor is not tolerated or is contraindicated.

A

1, 31

Recommended hypertension treatment for recurrent stroke prevention includes an ACE inhibitor and a diuretic.

A

1

Initial treatment of hypertension with an ACE inhibitor is recommended in patients with diabetes and chronic kidney disease.

A

1


ACE = angiotensin-converting enzyme.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 1205 or http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Combination therapy may be considered as the initial therapy to treat blood pressure that is more than 20/10 mm Hg over goal.

B

1, 3, 4

Combination therapy may be equally or better tolerated than higher doses of an individual component of the combination therapy.

B

4, 7, 12

The recommended initial treatment for hypertensive patients with heart failure or previous myocardial infarction includes a beta blocker and an ACE inhibitor.

A

1, 31, 32

For patients in whom an ACE inhibitor is recommended, an angiotensin receptor blocker may be substituted if the ACE inhibitor is not tolerated or is contraindicated.

A

1, 31

Recommended hypertension treatment for recurrent stroke prevention includes an ACE inhibitor and a diuretic.

A

1

Initial treatment of hypertension with an ACE inhibitor is recommended in patients with diabetes and chronic kidney disease.

A

1


ACE = angiotensin-converting enzyme.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 1205 or http://www.aafp.org/afpsort.xml.

Patients with comorbidities may benefit from the effects of different antihypertensive medications and warrant consideration for combination therapy. For example, a patient with hypertension and diabetes, heart failure, or renal disease may benefit from the combination of a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. When monotherapy fails to achieve target blood pressure, using combination therapy is an alternative to increasing the dose of a single agent1  (Table 11,10,11).

Table 1

Indications for Combination Therapy

Blood pressure is not at goal level on a single agent

Patient experiences adverse effects of single agent that may be improved by the addition of a second agent (e.g., adding an angiotensin-converting enzyme inhibitor to a calcium channel blocker to reduce peripheral edema)

Systolic blood pressure ≥ 20 mm Hg or diastolic blood pressure ≥ 10 mm Hg above goal

Compelling indication(s) present that may benefit from different mechanisms of action of multiple antihypertensives


Information from references 1, 10, and 11.

Table 1   Indications for Combination Therapy

View Table

Table 1

Indications for Combination Therapy

Blood pressure is not at goal level on a single agent

Patient experiences adverse effects of single agent that may be improved by the addition of a second agent (e.g., adding an angiotensin-converting enzyme inhibitor to a calcium channel blocker to reduce peripheral edema)

Systolic blood pressure ≥ 20 mm Hg or diastolic blood pressure ≥ 10 mm Hg above goal

Compelling indication(s) present that may benefit from different mechanisms of action of multiple antihypertensives


Information from references 1, 10, and 11.

Choice of Agents

A number of studies evaluated the effectiveness of different antihypertensive agents in decreasing all-cause mortality and, secondarily, decreasing cardiovascular morbidity and mortality. Although these studies often seek to establish the superiority of an agent or a combination of agents, interpretation of results is often complicated by differences in blood pressure lowering between treatment groups,1214 which alone could account for any observed benefit.15,16 Some trials draw conclusions about a single agent despite most study participants requiring treatment with multiple agents.13,17,18 Additional limitations include heterogeneous study populations and inherent differences in agents from the same class.15 This has led to debate in the literature and variation among clinical guidelines regarding initial, first-line, and second-line treatment recommendations. Because most patients with hypertension require more than one medication, choosing a “first-line” agent may be less important than identifying beneficial combinations for an individual patient.

The choice of antihypertensive agents is guided by clinical guidelines and patient characteristics (Table 2).1 The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial demonstrated the clinical- and cost-effectiveness of a thiazide diuretic as initial therapy.17 Thiazide diuretics are recommended as first-line pharmacologic treatment in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7),1  recognizing that most patients with hypertension will require a second agent in addition to the diuretic. A number of diuretic combinations are available (Table 319,20).

Table 2

Recommended Drug Classes for Specific Compelling Indications

Indication Diuretic Beta blocker Angiotensin-converting enzyme inhibitor Angiotensin receptor blocker Calcium channel blocker Aldosterone antagonist

Chronic kidney disease

X

X

Diabetes

X

X

X

X

X

Heart failure

X

X

X

X

X

High coronary disease risk

X

X

X

X

Postmyocardial infarction

X

X

X

Recurrent stroke prevention

X

X


Adapted with permission from Chobanian AV, Bakris GL, Black HR, et al.; for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1221.

Table 2   Recommended Drug Classes for Specific Compelling Indications

View Table

Table 2

Recommended Drug Classes for Specific Compelling Indications

Indication Diuretic Beta blocker Angiotensin-converting enzyme inhibitor Angiotensin receptor blocker Calcium channel blocker Aldosterone antagonist

Chronic kidney disease

X

X

Diabetes

X

X

X

X

X

Heart failure

X

X

X

X

X

High coronary disease risk

X

X

X

X

Postmyocardial infarction

X

X

X

Recurrent stroke prevention

X

X


Adapted with permission from Chobanian AV, Bakris GL, Black HR, et al.; for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1221.

Table 3

Combination Agents Available for Treatment of Hypertension

Combination Generic agent (trade name) Dosage (mg) Monthly cost of combination drug* Monthly cost of individual drugs*

ACE inhibitor/calcium channel blocker

Amlodipine/benazepril (Lotrel)

2.5/10

$85

$56/32

5/10

5/20

5/40

10/20

10/40

Max: 10/40

Enalapril/felodipine extended-release (Lexxel)

5/5

56

31/39

Max: 20/10

Trandolapril/verapamil extended-release (Tarka)

1/240

76

36/47

2/180

2/240

4/240

Max: 8/240

ACE inhibitor/diuretic

Benazepril/HCTZ (Lotensin HCT)

5/6.25

30

32/—

10/12.5

20/12.5

20/25

Max: 40/50

Captopril/HCTZ (Capozide)

25/15

24

23/—

25/25

50/15

50/25

Max: 150/50

Enalapril/HCTZ (Vaseretic)

5/12.5

32

31/13

10/25

Max: 20/50

Fosinopril/HCTZ (Monopril-HCT)

10/12.5

38

36/30

20/12.5

Max: 80/50

Lisinopril/HCTZ (Zestoretic)

10/12.5

33

18/13

20/12.5

20/25

Max: 80/50

Moexipril/HCTZ (Uniretic)

7.5/12.5

44

41/13

15/12.5

15/25

Max: 30/50

Quinapril/HCTZ (Accuretic)

10/12.5

37

37/13

20/12.5

20/25

Max: 40/25

Angiotensin receptor blocker/diuretic

Candesartan/HCTZ (Atacand HCT)

16/12.5

$74

$55/13

32/12.5

Max: 32/25

Eprosartan/HCTZ (Teveten HCT)

600/12.5

61

76/13

600/25

Max: 900/25

Irbesartan/HCTZ (Avalide)

150/12.5

68

56/13

300/12.5

Max: 300/25

Losartan/HCTZ (Hyzaar)

50/12.5

59

59/13

100/12.5

Max: 100/25

Olmesartan/HCTZ (Benicar HCT)

20/12.5

58

50/13

40/12.5

Max: 40/25

Telmisartan/HCTZ (Micardis HCT)

40/12.5

62

58/13

80/12.5

80/25

Max: 160/25

Valsartan/HCTZ (Diovan HCT)

80/12.5

66

62/13

160/12.5

160/25

320/12.5

Max: 320/25

Beta blocker/diuretic

Atenolol/chlorthalidone (Tenoretic)

50/25

26

26/7

Max: 100/25

Bisoprolol/HCTZ (Ziac)

2.5/6.25

34

5/6.25

10/6.25

Max: 20/12.5

Metoprolol/HCTZ (Lopressor HCT)

50/25

46

17/2

100/25

100/50

Max: 200/50

Nadolol/bendroflumethiazide (Corzide)

40/5

71

32/—

Max: 80/5

Propranolol/HCTZ (Inderide†)

40/25

46

14/2

80/25

Diuretic/diuretic

Amiloride/HCTZ (Moduretic†)

5/50

10

19/3

Max: 10/100

Spironolactone/HCTZ (Aldactazide)

25/25

15

14/2

50/50

Max: 200/200

Triamterene/HCTZ (Dyazide, Maxzide)

37.5/25

10

—/2

50/25

Max: 75/50

Vasodilator/diuretic

Hydralazine/HCTZ(Hydrazide)

25/25

13

15/2

50/50

Max: 200/100


ACE = angiotensin-converting enzyme; HCTZ = hydrochlorothiazide; Max = maximum dose recommended by manufacturer.

*—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar) in Red Book. Montvale, N.J.: Medical Economics Data, 2007. Cost to the patient will be higher, depending on prescription filling fee.

†—Brand no longer available in the United States.

Information from references 19 and 20.

Table 3   Combination Agents Available for Treatment of Hypertension

View Table

Table 3

Combination Agents Available for Treatment of Hypertension

Combination Generic agent (trade name) Dosage (mg) Monthly cost of combination drug* Monthly cost of individual drugs*

ACE inhibitor/calcium channel blocker

Amlodipine/benazepril (Lotrel)

2.5/10

$85

$56/32

5/10

5/20

5/40

10/20

10/40

Max: 10/40

Enalapril/felodipine extended-release (Lexxel)

5/5

56

31/39

Max: 20/10

Trandolapril/verapamil extended-release (Tarka)

1/240

76

36/47

2/180

2/240

4/240

Max: 8/240

ACE inhibitor/diuretic

Benazepril/HCTZ (Lotensin HCT)

5/6.25

30

32/—

10/12.5

20/12.5

20/25

Max: 40/50

Captopril/HCTZ (Capozide)

25/15

24

23/—

25/25

50/15

50/25

Max: 150/50

Enalapril/HCTZ (Vaseretic)

5/12.5

32

31/13

10/25

Max: 20/50

Fosinopril/HCTZ (Monopril-HCT)

10/12.5

38

36/30

20/12.5

Max: 80/50

Lisinopril/HCTZ (Zestoretic)

10/12.5

33

18/13

20/12.5

20/25

Max: 80/50

Moexipril/HCTZ (Uniretic)

7.5/12.5

44

41/13

15/12.5

15/25

Max: 30/50

Quinapril/HCTZ (Accuretic)

10/12.5

37

37/13

20/12.5

20/25

Max: 40/25

Angiotensin receptor blocker/diuretic

Candesartan/HCTZ (Atacand HCT)

16/12.5

$74

$55/13

32/12.5

Max: 32/25

Eprosartan/HCTZ (Teveten HCT)

600/12.5

61

76/13

600/25

Max: 900/25

Irbesartan/HCTZ (Avalide)

150/12.5

68

56/13

300/12.5

Max: 300/25

Losartan/HCTZ (Hyzaar)

50/12.5

59

59/13

100/12.5

Max: 100/25

Olmesartan/HCTZ (Benicar HCT)

20/12.5

58

50/13

40/12.5

Max: 40/25

Telmisartan/HCTZ (Micardis HCT)

40/12.5

62

58/13

80/12.5

80/25

Max: 160/25

Valsartan/HCTZ (Diovan HCT)

80/12.5

66

62/13

160/12.5

160/25

320/12.5

Max: 320/25

Beta blocker/diuretic

Atenolol/chlorthalidone (Tenoretic)

50/25

26

26/7

Max: 100/25

Bisoprolol/HCTZ (Ziac)

2.5/6.25

34

5/6.25

10/6.25

Max: 20/12.5

Metoprolol/HCTZ (Lopressor HCT)

50/25

46

17/2

100/25

100/50

Max: 200/50

Nadolol/bendroflumethiazide (Corzide)

40/5

71

32/—

Max: 80/5

Propranolol/HCTZ (Inderide†)

40/25

46

14/2

80/25

Diuretic/diuretic

Amiloride/HCTZ (Moduretic†)

5/50

10

19/3

Max: 10/100

Spironolactone/HCTZ (Aldactazide)

25/25

15

14/2

50/50

Max: 200/200

Triamterene/HCTZ (Dyazide, Maxzide)

37.5/25

10

—/2

50/25

Max: 75/50

Vasodilator/diuretic

Hydralazine/HCTZ(Hydrazide)

25/25

13

15/2

50/50

Max: 200/100


ACE = angiotensin-converting enzyme; HCTZ = hydrochlorothiazide; Max = maximum dose recommended by manufacturer.

*—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar) in Red Book. Montvale, N.J.: Medical Economics Data, 2007. Cost to the patient will be higher, depending on prescription filling fee.

†—Brand no longer available in the United States.

Information from references 19 and 20.

Antihypertensive agents can have complementary effects and may help offset each other's adverse effects. Combination therapies demonstrating synergistic or complementary mechanisms of action include beta blocker-diuretic;21 angiotensin receptor blocker (ARB)-diuretic;22,23 ACE inhibitor-diuretic;21 calcium channel blocker-ACE inhibitor;4,24,25 calcium channel blocker-diuretic;16 and a thiazide diuretic plus a potassium-sparing diuretic.21

A randomized controlled trial of hypertensive patients with increased cardiovascular risk evaluating treatment with amlodipine (Norvasc) plus perindopril (Aceon; a calcium channel blocker plus an ACE inhibitor, if needed) or atenolol (Tenormin) plus bendroflumethiazide (Naturetin; a beta blocker plus a diuretic, if needed), demonstrated that a calcium channel blocker-ACE inhibitor combination was superior to a beta blocker-diuretic combination in reducing cardiovascular morbidity and mortality and in preventing new-onset diabetes.26 However, the amlodipine-based treatment group achieved significantly lower blood pressure than the atenolol-based treatment group. Initial data of an ongoing trial comparing a combination pill containing a calcium channel blocker and an ACE inhibitor with a combination pill containing an ACE inhibitor and a diuretic on cardiovascular morbidity and mortality in patients with hypertension has demonstrated statistically significant blood pressure reductions using initial treatment combination therapy compared with the participants' pre-study enrollment antihypertensive drug regimens.27

Another randomized trial compared valsartan (Diovan), an ARB-based treatment, with amlodipine, a calcium channel blocker-based treatment, in patients with hypertension who are at an increased cardiovascular risk.16 Most participants required add-on therapy with hydrochlorothiazide plus other agents to achieve adequate blood pressure lowering. Despite improved blood pressure lowering in the amlodipine group, there was no decrease in cardiovascular morbidity or mortality between the study groups except for a decreased incidence of myocardial infarction in the patients treated with amlodipine.

The following combinations demonstrate particular risks: a nondihydropyridine calcium channel blocker with a beta blocker (risk of bradycardia),1 and an ACE inhibitor or ARB with an aldosterone antagonist (risk of hyperkalemia).28

Fixed-Dose Combination Agents

Fixed-dose combination treatments offer several potential benefits, including simplification of the treatment regimen, convenience, and sometimes decreased cost.1,8 The choice of combined agents can be used to minimize the adverse effects of each individual agent.8 An example is the combination of a thiazide diuretic with an ACE inhibitor.6

Disadvantages include initial doses that are often below those that would be started with monotherapy, making it potentially more difficult to achieve the desired dose, and the risk of causing orthostatic hypotension in older patients and patients with diabetic autonomic neuropathy.1 Patients' concerns about switching from combination therapy to a fixed-dose combination include: change in an established routine; ability to achieve the same medications and dosages in a combined pill; increased cost; inability to easily adjust the dose; and tablet size.29

Initial Management of Hypertension with Combination Therapy

Approximately 70 percent of patients with hypertension will require two or more agents to achieve their target blood pressure.6,26 Using combination therapy for initial management offers the potential to achieve target blood pressure9 with fewer adverse effects because lower doses of each agent may be used.7,12 Potential economic advantages include a reduced need to switch medications and improved long-term outcomes secondary to improved blood pressure control.30 Initial management with combination therapy should be considered in any patient whose blood pressure is greater than 20 mm Hg above systolic goal or 10 mm Hg above diastolic goal.1,3 The 2003 European Society of Hypertension-European Society of Cardiology guidelines offer a fixed-dose combination agent as an initial management option in patients with complicated and uncomplicated hypertension.10Figure 1 provides an algorithm for the management of hypertension.1

Algorithm for Hypertension Treatment

Figure 1.

Treatment algorithm for patients with hypertension.

*— Lifestyle modifications include tobacco cessation, weight loss, exercise, decreasing or eliminating alcohol consumption, and following the Dietary Approaches to Stop Hypertension (DASH) diet.

†— If patient is on more than one medication, consider titrating up a single agent at a time.

‡— Select additional agent per guidelines and individual patient characteristics.

Information from reference 1.

View Large

Algorithm for Hypertension Treatment


Figure 1.

Treatment algorithm for patients with hypertension.

*— Lifestyle modifications include tobacco cessation, weight loss, exercise, decreasing or eliminating alcohol consumption, and following the Dietary Approaches to Stop Hypertension (DASH) diet.

†— If patient is on more than one medication, consider titrating up a single agent at a time.

‡— Select additional agent per guidelines and individual patient characteristics.

Information from reference 1.

Algorithm for Hypertension Treatment


Figure 1.

Treatment algorithm for patients with hypertension.

*— Lifestyle modifications include tobacco cessation, weight loss, exercise, decreasing or eliminating alcohol consumption, and following the Dietary Approaches to Stop Hypertension (DASH) diet.

†— If patient is on more than one medication, consider titrating up a single agent at a time.

‡— Select additional agent per guidelines and individual patient characteristics.

Information from reference 1.

Special Populations

HEART FAILURE

JNC-7 guidelines recommend diuretics, beta blockers, ACE inhibitors, ARBs, and aldosterone antagonists (aldosterone antagonists include eplerenone [Inspra] and spironolactone [Aldactone]) in the treatment of hypertensive patients with heart failure.1 These medications have been shown to reduce morbidity and mortality in appropriately selected patients with heart failure. Aldosterone antagonists are beneficial in the treatment of moderate to severe heart failure, but may not offer the same benefit to patients with less severe heart failure or with significant renal failure.31 The use of ACE inhibitors, ARBs, and aldosterone antagonists in combination is not recommended because of the risk of hyperkalemia.31 ARBs may substitute for ACE inhibitors in patients unable to tolerate an ACE inhibitor.31 The choice of agents is based on severity of heart failure, left ventricular ejection fraction, and history of myocardial infarction.31

POSTMYOCARDIAL INFARCTION

The American College of Cardiology/American Heart Association guidelines recommend that treatment of patients with hypertension who have had a myocardial infarction include an ACE inhibitor, an ARB (for patients intolerant of ACE inhibitors), a beta blocker, and an aldosterone antagonist (for patients with symptomatic heart failure without hyperkalemia or significant renal failure).32 JNC-7 guidelines make similar recommendations.1 Short-acting calcium channel blockers are not recommended for the treatment of hypertension in postmyocardial infarction patients.32

HIGH RISK OF CORONARY DISEASE

In patients with hypertension at high risk of coronary disease, JNC-7 guidelines recommend the use of diuretics, calcium channel blockers, beta blockers, and ACE inhibitors.1 A study comparing the ACE inhibitor ramipril (Altace) with placebo in more than 10,000 patients with cardiovascular disease or at high coronary risk found a significant reduction in the risk of acute myocardial infarction, stroke, or death (14 versus 17.8 percent, number needed to treat [NNT] = 26 for five years).33 Another study comparing treatment with a calcium channel blocker-ACE inhibitor combination to a beta blocker-diuretic regimen in hypertensive patients with coronary artery disease demonstrated equivalent blood pressure lowering and no difference in cardiovascular morbidity and mortality.34 A randomized controlled trial of a valsartan-based anti-hypertensive regimen compared with conventional treatment with other agents (e.g., calcium channel blockers, ACE inhibitors, beta blockers) in Japanese patients with hypertension and an increased risk for or presence of cardiovascular disease demonstrated decreased cardiovascular morbidity in the valsartan-based group, despite equivalent blood pressure lowering (adjusted relative risk [ARR] = 3.7 percent, NNT = 27).35 There was no difference in all-cause or cardiovascular mortality.

DIABETES MELLITUS

Patients with hypertension and diabetes have lower rates of blood pressure control7 and often require combination therapy.1 JNC-7 guidelines recommend an ACE inhibitor or ARB (if an ACE inhibitor is not tolerated or is contraindicated) for these patients.1 Common combinations include an ACE inhibitor or ARB plus a calcium channel blocker36 or a diuretic.23 Given the low cost and proven benefits of a diuretic in reducing all-cause and cardiovascular mortality, the combination of a diuretic and an ACE inhibitor is a good starting point if combination therapy is chosen.

The calcium channel blocker-ACE inhibitor combination has demonstrated superior blood pressure lowering compared with ACE inhibitor monotherapy in patients with hypertension and diabetes.36,37 Renoprotection achieved in these patients by using ACE inhibitor treatment reflects the action of the ACE inhibitor and blood pressure lowering.13

The U.K. Prospective Diabetes Study Group found that blood pressure control was more important than tight blood glucose control at preventing cardiovascular events, and that an ACE inhibitor and a beta blocker were equivalent in their benefit, although 30 percent of patients in both groups required three or more medications to control their blood pressure.38 A study examining combination treatment with an ACE inhibitor-diuretic treatment compared with placebo was associated with a small decrease in vascular complications and significant blood pressure lowering of 5.6/2.2 mm Hg.39 Study participants with hypertension were continued on antihypertensive treatment regardless of treatment arm.39

CHRONIC KIDNEY DISEASE

Diabetes and hypertension are the two leading causes of end-stage renal disease.40 Hypertension can cause or worsen kidney disease, as well as be caused by kidney disease. Combination therapy is often needed to effectively lower blood pressure to goal levels in patients with kidney disease because monotherapy rarely attains the level of blood pressure lowering required to slow the decline in glomerular filtration rate.40,41 First-line therapy for proteinuric kidney disease includes an ACE inhibitor or ARB, and often requires the addition of a diuretic or a calcium channel blocker.41,42 In patients with hypertension and nondiabetic proteinuric kidney disease, addition of a calcium channel blocker to an ACE inhibitor achieved greater blood pressure reduction, but did not offer an advantage in decreasing the progression to end-stage renal disease.43 Thiazide diuretics are recommended in patients with a glomerular filtration rate greater than or equal to 40 mL per minute per 1.73 m2 (body surface area), and loop diuretics are recommended in patients with a glomerular filtration rate less than or equal to 40 to 50 mL per minute per 1.73 m2.28,42 The combination of an ACE inhibitor and an ARB may be beneficial compared with either agent alone in certain patients with chronic kidney disease.28,42,44 In initial trials, patients already taking an ARB or an ACE inhibitor experienced decreased proteinuria with the addition of an aldosterone antagonist, although this combination may increase potassium levels and its use needs to be supported by larger studies.28

Recurrent Stroke Prevention

JNC-7 guidelines recommend diuretics and ACE inhibitors for secondary stroke prevention.1 A randomized study evaluating the effectiveness of treatment with an ACE inhibitor for decreasing recurrent stroke found that treatment with an ACE inhibitor plus a diuretic (required by most of the study participants) significantly decreased recurrent stroke incidence.14 The participants who received combination therapy experienced significantly greater blood pressure lowering compared with participants who received ACE inhibitor monotherapy.

In a study evaluating an ARB versus a calcium channel blocker for secondary stroke prevention, two thirds of patients in both treatment arms required at least one additional agent to achieve adequate blood pressure lowering.45 Despite equivalent blood pressure lowering in both groups, patients in the ARB-based treatment group had a lower incidence of stroke (ARR = 8 percent, NNT = 12.5).

The Author

JENNIFER FRANK, MD, is an assistant professor of family medicine at the University of Wisconsin School of Medicine and Public Health in Madison, and a faculty member at the Fox Valley Family Medicine Residency Program in Appleton, Wisc. Dr. Frank received her medical degree from Boston University School of Medicine and completed her family medicine residency at DeWitt Army Community Hospital in Fort Belvoir, Va. She spent four years at Martin Army Community Hospital in Fort Benning, Ga., where she served as a residency faculty member while on active duty in the U.S. Army.

Author disclosure: Dr. Frank owned stock in Pfizer at the time the manuscript was written.

Address correspondence to Jennifer Frank, MD, 229 S. Morrison St., Appleton, WI 54911 (e-mail: Jennifer.frank@fammed.wisc.edu). Reprints are not available from the author.

REFERENCES

1. Chobanian AV, Bakris GL, Black HR, et al., for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.

2. Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich). 2006;8(9):634–641.

3. Bakris GL, Weir MR, Black HR. Improving blood pressure control rates: is there more we can do? J Clin Hypertens (Greenwich). 2007;9(2):134–142.

4. Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004;17(6):495–501.

5. Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther. 2005;27(7):1013–1021.

6. Taylor AA. Combination drug treatment of hypertension: have we come full circle? Curr Cardiol Rep. 2004;6(6):421–426.

7. Giles TD. Rationale for combination therapy as initial treatment for hypertension. J Clin Hypertens (Greenwich). 2003;5(4)(suppl 3):4–11.

8. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996;156(17):1969–1978.

9. Elliott WJ. Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep. 2002;4(4):278–285.

10. Erdine S, Ari O, Zanchetti A, et al. ESH-ESC guidelines for the management of hypertension. Herz. 2006;31(4):331–338.

11. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002;15(6):550–556.

12. Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27(5):578–587.

13. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol. 2006;17(12):3472–3481.

14. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack [published corrections appear in Lancet. 2001;358(9292):1556 and Lancet. 2002;359(9323):2120]. Lancet. 2001;358(9287):1033–1041.

15. Gallagher M, Perkovic V, Chalmers J. Diuretics: a modern day treatment option? Nephrology (Carlton). 2006;11(5):419–427.

16. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031.

17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289(2):178 and JAMA. 2004;291(18):2196]. JAMA. 2002;288(23):2981–2997.

18. Wright JT Jr, Bakris G, Greene T, et al., for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial [published correction appears in JAMA. 2006;295(23):2726]. JAMA. 2002;288(19):2421–2431.

19. Drug information. MD Consult. http://home.mdconsult.com/das/pharm/view/68957037-2. Accessed December 10, 2007.

20. United States Food and Drug Administration. Human drugs. Center for Drug Evaluation and Research. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed October 10, 2007.

21. Padilla MC, Armas-Hernández MJ, Hernández RH, Israili ZH, Valasco M. Update on diuretics in the treatment of hypertension. Am J Ther. 2007;14(2):154–160.

22. Weir MR, Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(2):103–112.

23. Sowers JR, Neutel JM, Saunders E, et al., for the INCLUSIVE Investigators. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006;8(7):470–480.

24. Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs. 2007;67(1):95–106.

25. Nash DT. Systolic hypertension. Geriatrics. 2006;61(12):22–28.

26. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.

27. Jamerson K, Bakris GL, Dahlöf B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16(2):80–86.

28. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49(1):12–26.

29. Williams B, Shaw A, Durrant R, Crinson I, Pagliari C, de Lusignan S. Patient perspectives on multiple medications versus combined pills: a qualitative study. QJM. 2005;98(12):885–893.

30. Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics. 2001;19(4):337–347.

31. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) [published correction appears in J Am Coll Cardiol. 2006;47(7):1503–1505]. J Am Coll Cardiol. 2005;46(6):e1–e82.

32. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44(3):E1–E211.

33. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342(18):1376, and N Engl J Med. 2000;342(10):748]. N Engl J Med. 2000;342(3):145–153.

34. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–2816.

35. Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571):1431–1439.

36. Tobe S, Kawecka-Jaszcz K, Zannad F, Vetrovec G, Patni R, Shi H. Amlodipine added to quinapril vs. quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. J Clin Hypertens (Greenwich). 2007;9(2):120–127.

37. Bakris GL, Weir MR, for the Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003;5(3):202–209.

38. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317(7160):713–720.

39. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840.

40. Flack JM, Peters R, Mehra VC, Nasser SA. Hypertension in special populations. Cardiol Clin. 2002;20(2):303–319, vii.

41. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials BMJ. 2003;326(7404):1427.

42. Zamboli P, De Nicola L, Minutolo R, Bertino V, Catapano F, Conte G. Management of hypertension in chronic kidney disease. Curr Hypertens Rep. 2006;8(6):497–501.

43. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939–946.

44. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005;45(5):880–886.

45. Schrader J, Lüders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36(6):1218–1226.

This is one in a series of “Clinical Pharmacology” articles coordinated by Allen F. Shaughnessy, PharmD, Tufts University Family Medicine Residency at Cambridge Health Alliance, Malden, Mass.



Copyright © 2008 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article